Evidence map›Paper›PMID 40741108›Full record

ReviewiLIVER2025

The application of liver cancer organoids in tumour precision medicine: A comprehensive review.

Jiaye Mo, Da Gong, Mei Zhai, Jintao Yang, Zhike Li, Meilong Wu, Xuesong Deng, Xiaoyong Dai

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in iLIVER, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jiaye MoGraduate School, Guangxi University of Chinese Medicine, Nanning 530200, Guangxi, China.
Da GongDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Shenzhen University, Health Science Center, Shenzhen Second People's Hospital, Shenzhen 518035, Guangdong, China.
Mei ZhaiDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Shenzhen University, Health Science Center, Shenzhen Second People's Hospital, Shenzhen 518035, Guangdong, China.
Jintao YangThe Second Clinical Medical College of Jinan University, Department of General Surgery, Shenzhen People's Hospital, Shenzhen 518020, Guangdong, China.
Zhike LiThe Second Clinical Medical College of Jinan University, Department of General Surgery, Shenzhen People's Hospital, Shenzhen 518020, Guangdong, China.
Meilong WuDivision of Hepatobiliary and Pancreatic Surgery, Department of General Surgery, Shenzhen People's Hospital (the Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen 518020, Guangdong, China.
Xuesong DengGraduate School, Guangxi University of Chinese Medicine, Nanning 530200, Guangxi, China.
Xiaoyong DaiDepartment of Physiology, School of Medicine, and State Key Laboratory of Bioactive Molecules and Druggability Assessment, Jinan University, Guangzhou 510632, Guangdong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liver cancer is a leading cause of cancer-related death worldwide, and its complexity and heterogeneity pose considerable challenges to conventional treatment. In recent years, the rise of organoid technology has provided new perspectives and tools for precision medicine in oncology. The use of high-fidelity organoids capable of recapitulating patients' genotypic and phenotypic features can further facilitate personalised treatment. In this review, we discuss 1) the advantages of liver cancer organoids as disease models over traditional models; 2) the origin and establishment of liver cancer organoids; 3) the application of liver cancer organoids technology in tumour precision medicine; 4) the technical tools of liver cancer-derived organoids; and 5) current solutions for the deficiencies and challenges of liver cancer organoids. This review should provide both a deeper understanding of the research progress and application prospects of liver cancer organoids, as well as theoretical support and practical guidance for more complete integration of liver cancer research and precision medicine.

Indexed as

3D bioprintingDrug screeningLiver cancerLiver cancer organoidsMicrofluidic chipsPrecision medicine

Identifiers

PMID40741108
PMCPMC12305244

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.